FrancophonIA/ELRC3.0 huggingface dataset:
English: Severe neutropenia (neutrophil count <0.5 X 109/L) has been reported in quetiapine clinical trials.
Estonian: Kvetiapiini lühiajalistes platseebokontrolliga monoravi kliinilistes uuringutes on tekkinud rasket neutropeenia (neutrofiilide arv <0,5 x 109/l).
English: The recommended daily dose is 300 mg.
Estonian: 4. päeval 300 mg.
English: • Epilepsy medicines (like phenytoin or carbamazepine).
Estonian: PVC+PCTFE/Al blisterpakendid.
English: Two short-term (6 week) studies enrolled patients who had shown an inadequate response to at least one antidepressant.
Estonian: Vastav tähelepanek leidis kinnitust vähemalt 21 kuud eksponeeritud olnud patsientidel.
English: Seroquel XR 50 mg prolonged-release tablets quetiapine
Estonian: RAVIMPREPARAADI NIMETUS Seroquel XR, 50 mg toimeainet prolongeeritult vabastavad tabletid quetiapinum
English: Agranulocytosis
Estonian: Neerukahjustus
English: Constipation and intestinal obstruction have been reported with quetiapine (see section 4.8 Undesirable effects).
Estonian: Kvetiapiini kasutamisel on teatatud kõhukinnisuse ja soolesulguse tekkest (vt lõik 4.8).
English: The total daily dose for the first four days of therapy is 100 mg (Day 1), 200 mg (Day 2), 300 mg (Day 3) and 400 mg (Day 4).
Estonian: Esimesel neljal ravipäeval on ööpäevane annus järgmine: 1. päeval 100 mg;
English: Men and women to have swelling of breasts and unexpectedly produce breast milk.
Estonian: - poisslastel ja tütarlastel rindade turset ja ootamatut eritist rinnast;
English: Major depressive episodes in MDD
Estonian: Depressiooni täiendravi
English: • If you get any side effects talk to your doctor or pharmacist.
Estonian: - Kui teil tekib ükskõik milline kõrvaltoime, pidage nõu oma arsti või apteekriga.
English: Thrombocytope nia, Anaemia, platelet count decreased13
Estonian: Trombotsütopeenia, aneemia, trombotsüütide arvu langus (13)
English: Each tablet contains 300 mg quetiapine (as fumarate)
Estonian: TOIMEAINE(TE) SISALDUS Üks tablett sisaldab 300 mg kvetiapiini (kvetiapiinfumaraadina).
English: Elderly:
Estonian: Kehakaal:
English: • Fits or seizures
Estonian: Kae/läätsehägusus
English: Do not take Seroquel XR if the above applies to you.
Estonian: Kui ülaltoodu käib teie kohta, ärge kasutage Seroquel XRi.
English: May lead to falls 17.
Estonian: Võib põhjustada kukkumisi.
English: In placebo-controlled studies in elderly patients with dementia-related psychosis, the incidence of cerebrovascular adverse events per 100 patient years was not higher in quetiapine-treated patients than in placebo-treated patients.
Estonian: Dementsusega seotud psühhoosiga vanemaealiste patsientide seas teostatud platseebokontrolliga uuringutes ei erinenud haigestumus ajuveresoontega seotud kõrvaltoimetesse kvetiapiini- ning platseeborühma vahel.
English: These include difficulty starting muscle movements, shaking, feeling restless or muscle stiffness without pain.
Estonian: - söögiisu tõus; - oksendamine; - ebanormaalsed liigutused lihastes (raskus liigutuste alustamisel, värisemine, rahutus või jäikus lihastes ilma valuta); - vererõhutõus.
English: • Allergic reactions that may include raised lumps (weals), swelling of the skin and swelling around the mouth.
Estonian: • ebanormaalsed liigutused lihastes (raskus liigutuste alustamisel, värisemine või jäikus lihastes ilma valuta);
English: Extrapyramidal symptoms3, 4
Estonian: Ekstrapüramidaalsed sümptomid
English: Paediatric Population:
Estonian: Maksakahjustusega patsiendid:
English: Treatment with Seroquel was initiated at 50 mg/day and on day 2 increased to
Estonian: Eakatel tuleb ravi Seroquel XRiga alustada annusega 50 mg/ööpäevas.
English: Each tablet contains 150 mg quetiapine (as fumarate)
Estonian: TOIMEAINE(TE) SISALDUS Üks tablett sisaldab 150 mg kvetiapiini (kvetiapiinfumaraadina).
English: Information from a sixth study that was submitted during the procedure was also considered.
Estonian: Arvesse võeti ka menetluse ajal esitatud kuuenda uuringu andmeid.
English: In addition, Trulicity has the advantage of being given once a week.
Estonian: Trulicity eelis on ka see, et seda manustatakse üks kord nädalas.
English: Trulicity dulaglutide
Estonian: Trulicity dulaglutiid
English: The European Commission granted a marketing authorisation valid throughout the European Union for Trulicity on 21 November 2014.
Estonian: Euroopa Komisjon andis Trulicity müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 21. novembril 2014.
English: The full EPAR and risk management plan summary for Trulicity can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Trulicity kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Trulicity is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Trulicity võimalikult ohutu kasutamine.
English: Other information about Trulicity
Estonian: Muu teave Trulicity kohta
English: What measures are being taken to ensure the safe and effective use of Trulicity?
Estonian: Mis meetmed võetakse, et tagada Trulicity ohutu ja efektiivne kasutamine?
English: The benefits of Trulicity have been studied in 5 main studies involving over 4,500 patients with type 2 diabetes.
Estonian: Trulicity kasulikkust uuriti 5 põhiuuringus, milles osales üle 4500 II tüüpi diabeediga patsiendi.
English: This was considered to be clinically meaningful and there was evidence that the benefits were maintained during long-term treatment.
Estonian: Seda peeti kliiniliselt oluliseks ja andmed näitasid, et see toime püsis ka pikaajalise ravi korral.
English: With respect to safety, effects of longer term use and safety in vulnerable groups such as the very elderly would need to be monitored, but there were no specific areas of major concern and the risks were considered similar to those of other medicines in its class.
Estonian: Suurema riski rühmades, nt väga eakad, tuleb jälgida pikemaajalise kasutamise toimet ja ohutust, kuid konkreetsed probleemsed valdkonnad puudusid ja riske peeti sarnaseks teiste sama rühma ravimite riskidega.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Trulicity's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Trulicity kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Why is Trulicity approved?
Estonian: Miks Trulicity heaks kiideti?
English: What is Trulicity and what is it used for?
Estonian: Mis on Trulicity ja milleks seda kasutatakse?
English: The patients' average HbA1c at baseline ranged from 7.6 to 8.5% and patients were treated for at least 52 weeks.
Estonian: Patsientide keskmise HbA1c sisalduse algväärtus oli vahemikus 7,68,5% ja patsiente raviti vähemalt 52 nädalat.
English: What are the risks associated with Trulicity?
Estonian: Mis riskid Trulicityga kaasnevad?
English: This is a summary of the European public assessment report (EPAR) for Trulicity.
Estonian: See on ravimi Trulicity Euroopa avaliku hindamisaruande kokkuvõte.
English: The most common side effects with Trulicity (which may affect more than 1 in 10 people) are nausea (feeling sick), vomiting and diarrhoea.
Estonian: Trulicity kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on iiveldus, oksendamine ja kõhulahtisus.
English: The recommended dose is 0.75 mg injected once a week when used on its own, and 1.5 mg once a week in combination with other diabetes medicines (although doctors may begin with the lower dose in patients at potentially greater risk such as those aged over 75).
Estonian: Soovitatav annus on 0,75 mg süstituna üks kord nädalas, kui seda kasutatakse ainsa ravimina, ja 1,5 mg üks kord nädalas kombinatsioonis teiste diabeediravimitega (kuid arst võib alustada väiksema annusega suurema potentsiaalse riskiga patsientidel, nt üle 75-aastastel).
English: It works by attaching to receptors for a substance called glucagon-like peptide 1 (GLP-1), which are found on the surface of the cells in the pancreas and stimulate them to release insulin.
Estonian: See seondub glükagoonilaadse peptiidi 1 (GLP-1) retseptoritega, mis paiknevad kõhunäärme rakkude pinnal ja stimuleerivad insuliini vabanemist.
English: Patients inject the medicine themselves (after suitable training) under the skin in the abdomen or thigh.
Estonian: Patsiendid süstivad ravimit (pärast piisava väljaõppe saamist) endale ise nahaaluse süstina kõhupiirkonda või reide.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Trulicity, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Trulicity omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: HbA1c gives an indication of how well the blood glucose is controlled.
Estonian: HbA1c sisaldus näitab, kui hästi on vere glükoosisisalduse reguleeritavust.
English: It is not intended to provide practical advice on how to use Trulicity.
Estonian: Hindamisaruandes ei anta Trulicity kasutamise praktilisi nõuandeid.
English: When Trulicity is injected, dulaglutide reaches the receptors in the pancreas and activates them.
Estonian: Trulicity süstimise järel jõuab dulaglutiid kõhunäärmes paiknevate retseptoriteni ja aktiveerib need.
English: Trulicity is available as prefilled pens (0.75 mg and 1.5 mg) containing a solution to be injected under the skin.
Estonian: Trulicityt turustatakse eeltäidetud pen-süstlites (0,75 mg ja 1,5 mg), mis sisaldavad naha alla süstitavat lahust.
English: The main measure of effectiveness was the change in the level of glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood that has glucose attached.
Estonian: Efektiivsuse põhinäitaja oli muutus glükohemoglobiini (HbA1c) sisalduses, mis näitab, kui suur protsent hemoglobiinist veres on seondunud glükoosiga.
English: In these studies Trulicity was compared with placebo (a dummy treatment) or with other diabetes medicines when used alone or as an add-on to various combination treatments.
Estonian: Nendes uuringutes võrreldi Trulicityt platseebo (näiv ravim) või teiste diabeediravimitega, kui seda kasutati ainsa ravimina või mitmesuguste kombinatsioonravide täiendava ravimina.
English: Trulicity can be used on its own in patients whose blood glucose levels are not satisfactorily controlled on diet and exercise alone and who cannot take metformin (another diabetes medicine).
Estonian: Trulicityt tohib kasutada ainsa ravimina patsientidel, kelle vere glükoosisisaldust ei saa üksnes dieedi ja kehalise koormusega piisavalt reguleerida ja kes ei talu metformiini (teine diabeediravim).
English: How does Trulicity work?
Estonian: Kuidas Trulicity toimib?
English: After 26 weeks of treatment, Trulicity reduced HbA1c by between 0.71 and 1.59 percentage points at the lower dose, and by between 0.78 and 1.64 percentage points at the higher dose.
Estonian: 26 ravinädala järel vähendas Trulicity väiksem annus HbA1c sisaldust 0,71-1,59 protsendipunkti ja suurem annus 0,78-1,64 protsendipunkti.
English: Trulicity was more effective than metformin at reducing HbA1c levels when used alone, and was more effective than the diabetes medicines exenatide (given twice daily) or sitagliptin, and at least as good as insulin glargine, when used as add-on to other treatments.
Estonian: HbA1c sisalduse vähendamisel oli Trulicity ainsa ravimina kasutamisel efektiivsem kui metformiin ning efektiivsem kui diabeediravimid eksenatiid (manustatuna kaks korda ööpäevas) ja sitagliptiin ning vähemalt sama efektiivne kui glargiininsuliin, mida kasutati muude ravimite lisaravimina.
English: For the full list of all side effects and restrictions with Trulicity, see the package leaflet.
Estonian: Trulicity kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: The active substance in Trulicity, dulaglutide, is a ‘GLP-1 receptor agonist'.
Estonian: Trulicity toimeaine dulaglutiid on GLP-1 retseptori agonist.
English: Trulicity is a diabetes medicine used in adults with type 2 diabetes to control their blood glucose (sugar) level.
Estonian: Trulicity on diabeediravim, mida kasutatakse II tüüpi diabeediga täiskasvanud patsientide raviks, et reguleerida nende vere glükoosisisaldust.
English: For practical information about using Trulicity, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Trulicity kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Trulicity, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Trulicityga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It can also be used as an ‘add-on' to other diabetes medicines, including insulin, when these medicines together with exercise and diet are not providing adequate control of blood glucose.
Estonian: Trulicityt tohib kasutada lisaks muudele diabeediravimitele, sh insuliinile, kui need ravimid koos dieedi ja kehalise koormusega ei reguleeri piisavalt vere glükoosisisaldust.
English: About 51% of those given the lower dose and 60% of patients given the higher dose of Trulicity achieved a target HbA1c below 7.0% and this was generally more than the proportion achieving this target with alternative treatments.
Estonian: Ligikaudu 51% Trulicity väiksema annuse saanud patsientide ja 60% suurema annuse saanud patsientide HbA1c sisaldus vähenes alla 7,0% ja selliste patsientide osakaal oli üldiselt suurem kui muude ravimeetodite korral.
English: The Committee noted that the medicine produces a significant and clinically relevant effect in controlling blood glucose when used with other medicines.
Estonian: Komitee märkis, et teiste ravimitega koos kasutamisel on Trulicity efektiivsus vere glükoosisisalduse reguleerimisel on märkimisväärne ja kliiniliselt oluline.
English: What benefits of Trulicity have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Trulicity kasulikkus?
English: Trulicity contains the active substance dulaglutide.
Estonian: Trulicity toimeaine on dulaglutiid.
English: How is Trulicity used?
Estonian: Kuidas Trulicityt kasutatakse?
English: However, when used alone in patients who cannot take metformin, or when used in very elderly patients (aged over 75), the ratio of benefit to risk was greatest at the lower dose.
Estonian: Ravimi üks kord nädalas manustatud annus 1,5 mg oli efektiivsem kui 0,75 mg, ent kui Trulicityt kasutati ainsa ravimina patsientidel, kes metformiini ei tohtinud võtta, või kui seda manustati eakatele patsientidele (üle 75-aastased), oli kasulikkuse ja riski suhe suurim väikse annuse korral.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom with a type of diabetes medicine called a sulphonylurea or with insulin, the dose of the sulphonylurea or insulin may need to be lowered to avoid hypoglycaemia (low blood sugar levels).
Estonian: Trulicityt kasutatakse kombinatsioonis sulfonüüluurearavimi (samuti diabeediravim) või insuliiniga, võib olla vaja nende ravimite annuseid vähendada, et vältida hüpoglükeemia (vere vähene glükoosisisaldus) tekkevõimalust.
English: When used in combination
Estonian: Kui
English: The medicine can only be obtained with a prescription.
Estonian: Trulicity on retseptiravim.
English: 340 ml (0.5 mg/ml) 1 bottle + 2 syringes + 1 bottle adapter
Estonian: 340 ml (0,5 mg/ml) 1 pudel + 2 süstalt +
English: Immediate Packaging
Estonian: 1 pudeliadapter
English: Oral suspension Oral use bottle (PET)
Estonian: 0,5 mg/ml Suukaudne suspensioon pudel (PET)
English: The European Commission granted a marketing authorisation valid throughout the EU for Imprida on 17 January 2007.
Estonian: Euroopa Komisjon andis Imprida müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 17. jaanuaril 2007.
English: The full EPAR for Imprida can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Imprida kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Imprida
Estonian: Muu teave Imprida kohta
English: Imprida is taken by mouth as one tablet once a day with some water.
Estonian: Impridat võetakse suu kaudu üks tablett üks kord ööpäevas koos vähese veega.
English: The CHMP decided that Imprida's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Imprida kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Imprida amlodipine / valsartan
Estonian: Imprida amlodipiin/valsartaan
English: For more information about treatment with Imprida, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Impridaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Imprida.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The most common side effects with Imprida (seen in between 1 and 10 patients in 100) are headache, nasopharyngitis (inflammation of the nose and throat), influenza (flu), hypokalaemia (low blood potassium levels), various types of oedema (swelling), fatigue (tiredness), flushing (reddening), asthenia (weakness) and hot flushes.
Estonian: Imprida kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on peavalu, nasofarüngiit (nina-neelupõletik), gripp, hüpokaleemia (vere kaaliumivaegus), mitmesugused tursed, väsimus, nahapunetus, asteenia (nõrkus) ja kuumahood.
English: What is the risk associated with Imprida?
Estonian: Mis riskid Impridaga kaasnevad?
English: For the full list of all side effects reported with Imprida, see the package leaflet.
Estonian: Imprida kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What is Imprida?
Estonian: Mis on Imprida?
English: Imprida must not be used in patients who have severe liver or bile problems, patients with certain heart problems and patients with severe hypotension (low blood pressure).
Estonian: Impridat ei tohi kasutada patsiendid, kellel on rasked maksavõi sapiprobleemid, teatud südameprobleemidega patsiendid ega raske hüpotensiooniga (madala vererõhuga) patsiendid.
English: Why has Imprida been approved?
Estonian: Miks Imprida heaks kiideti?
English: Imprida is a medicine that contains two active substances, amlodipine and valsartan.
Estonian: Imprida on ravim, mis sisaldab kahte toimeainet, amlodipiini ja valsartaani.
English: The company also presented evidence that the levels of amlodipine and valsartan in the blood were the same in people taking Imprida and people taking the separate medicines.
Estonian: Ettevõte esitas ka andmeid, et amlodipiini ja valsartaani sisaldus veres oli Impridat kasutavatel ning amlodipiini ja valsartaani eraldi kasutavatel patsientidel ühesugune.
English: By lowering the blood pressure, the risks associated with by high blood pressure, such as having a stroke, are reduced.
Estonian: Vererõhu alanemisel vähenevad kõrgvererõhuga seotud riskid, näiteks insuldirisk.
English: Imprida must not be used in patients who are hypersensitive (allergic) to amlodipine or other medicines in the ‘dihydropyridine derivatives' class, to valsartan, or to any of the other ingredients.
Estonian: Impridat ei tohi kasutada patsiendid, kes on amlodipiini või teiste dihüdropüridiini derivaatide klassi kuuluvate ravimite, valsartaani või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Imprida is used in patients who have essential hypertension (high blood pressure) that is not adequately controlled on either amlodipine or valsartan taken alone.
Estonian: Impridat kasutatakse essentsiaalse hüpertensiooniga (kõrgvererõhutõvega) patsientidel, kelle vererõhku ei saa ainult amlodipiini või valsartaaniga piisavalt reguleerida.
English: This is a summary of the European public assessment report (EPAR) for Imprida.
Estonian: See on ravimi Imprida Euroopa avaliku hindamisaruande kokkuvõte.
English: What benefit has Imprida shown during the studies?
Estonian: Milles seisneb uuringute põhjal Imprida kasulikkus?
English: Imprida contains two active substances, amlodipine and valsartan.
Estonian: Imprida sisaldab kahte toimeainet, amlodipiini ja valsartaani.
English: What is Imprida used for?
Estonian: Milleks Impridat kasutatakse?
English: How is Imprida used?
Estonian: Kuidas Impridat kasutatakse?
English: The medicine can only be obtained with a prescription
Estonian: Imprida on retseptiravim.
English: The dose of Imprida to be used depends on the doses of amlodipine or valsartan that the patient was taking before.
Estonian: Imprida annus sõltub patsiendi varasemast amlodipiini või valsartaani annusest.
English: Imprida must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with type 2 diabetes or in patients with moderate or severe kidney impairment.
Estonian: II tüüpi diabeediga või mõõduka või raske neerupuudulikkusega patsiendid ei tohi kasutada Impridat koos aliskireeni sisaldavate ravimitega (essentsiaalse hüpertensiooni ravimid).
English: 16 January, 2014
Estonian: 16. jaanuar 2014
English: • if you are 75 years old or older, you should not start taking this medicine.
Estonian: • kui te olete 75-aastane või vanem, siis te ei tohi alustada ravi selle ravimiga.
English: The majority of these reactions were transient and reversible.
Estonian: Enamus nendest kõrvaltoimetest olid ajutised ja pöörduvad.
English: More information is given below in ‘Other medicines and Xigduo'.
Estonian: Rohkem teavet on esitatud allpool lõigus „Muud ravimid ja Xigduo“;
English: Dapagliflozin is approximately 91 % protein bound.
Estonian: Dapagliflosiin seondub ligikaudu 91% ulatuses valkudega.
English: • if you have “type 1 diabetes” - the type that usually starts when you are young, and your body does not produce any insulin.
Estonian: • kui teil esineb 1. tüüpi suhkurtõbi - haiguse tüüp, mis algab tavaliselt noores eas ja mille korral teie organism ei tooda insuliini;
English: This medicine has no or negligible influence on the ability to drive and use machines.
Estonian: See ravim ei mõjuta või mõjutab tühisel määral autojuhtimise ning masinate käsitsemise võimet.
English: Body weight reductions were sustained in long-term extensions up to 208 weeks.
Estonian: Kehakaalu vähenemine püsis pikaajalisel, kuni 208-nädalase kestusega jätkuperioodil.
English: • If renal function falls below GFR < 60 mL/min, treatment should be discontinued.
Estonian: • kui neerufunktsioon langeb alla CrCl < 60 ml/min, tuleb ravi katkestada;
English: • These are medicines taken by mouth for diabetes.
Estonian: • Need on ravimid, mida võetakse suhkurtõve puhul suu kaudu.
English: • changes in laboratory blood tests (creatinine or urea)
Estonian: • muutused laboratoorsetes veretestides (kreatiniin või uurea);
English: Furthermore, two 12-week, placebo-controlled studies were conducted in patients with inadequately controlled type 2 diabetes and hypertension.
Estonian: Lisaks viidi läbi kaks 12nädalast kontrollrühmaga uuringut puudulikult kontrollitud 2. tüüpi diabeedi ja kõrgvererõhutõvega patsientidel.